Article
Oncology
Thomas Chevalier, Amaury Daste, Esmaa Saada-Bouzid, Anderson Loundou, Florent Peyraud, Tiphaine Lambert, Christophe Le Tourneau, Frederic Peyrade, Charlotte Dupuis, Marc Alfonsi, Jerome Fayette, Juliette Reure, Florence Huguet, Nicolas Fakhry, Clemence Toullec, Sebastien Salas
Summary: The study demonstrated that adding cetuximab to paclitaxel chemotherapy can improve the survival of patients with recurrent or metastatic head and neck squamous cell carcinoma, which was confirmed in the matched-paired population. Furthermore, for patients who have received cetuximab maintenance therapy for more than 3 months, the paclitaxel+cetuximab regimen was associated with better survival outcomes.
Article
Oncology
Wing-Lok Chan, Cheuk-Wai Choi, Ian Yu-Hong Wong, Terence Hon-Ting Tsang, Adrian Tin-Chung Lam, Rosa Pui-Ying Tse, K. K. Chan, Claudia Wong, Betty Tze-Ting Law, Emina Edith Cheung, Siu-Yin Chan, Ka-On Lam, Dora Kwong, Simon Law
Summary: This study reviewed the long-term clinical outcomes and safety data of induction chemotherapy followed by surgery or definitive chemoradiotherapy in patients with locally advanced unresectable esophageal cancer. The results showed that patients who received subsequent surgery had significantly longer median overall survival compared to those who had definitive chemoradiotherapy or no definitive treatment. Induction chemotherapy followed by conversion surgery offered a chance of cure with long-term survival benefit and manageable toxicities in these patients.
ANNALS OF SURGICAL ONCOLOGY
(2023)
Article
Oncology
Steve Nicholson, Holly Tovey, Tony Elliott, Stephanie M. Burnett, Clare Cruickshank, Amit Bahl, Peter Kirkbride, Anita V. Mitra, Alastair H. Thomson, Naveen Vasudev, Balaji Venugopal, Rachel Slade, Lucy Tregellas, Bruno Morgan, Alison Hassall, Emma Hall, Lisa M. Pickering
Summary: This study investigated the first-line activity of vinflunine in patients with penile cancer, showing promising results with a clinical benefit rate of 45.5%. Despite some toxicity issues, the study concludes that vinflunine warrants further investigation for this disease.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Tomofumi Naruse, Souichi Yanamoto, Mitsunobu Otsuru, Nobuhiro Yamakawa, Tadaaki Kirita, Yukari Shintani, Tatsushi Matsumura, Masaya Okura, Masashi Sasaki, Yoshihide Ota, Shin-ichi Yamada, Hiroshi Kurita, Masahiro Umeda
Summary: The study suggests that the weekly cetuximab plus paclitaxel regimen may be a treatment option for patients with recurrent or metastatic oral squamous cell carcinoma that is refractory to platinum-based chemotherapy or progressive disease after chemotherapy. Adverse events were tolerable and manageable, with overall efficacy being relatively promising.
ANTICANCER RESEARCH
(2021)
Article
Biochemistry & Molecular Biology
Nabil F. Saba, Conor E. Steuer, Asari Ekpenyong, Ashley McCook-Veal, Kelly Magliocca, Mihir Patel, Nicole C. Schmitt, William Stokes, James E. Bates, Soumon Rudra, Jill Remick, Mark McDonald, Marin Abousaud, Aik Choon Tan, Muhammad Zaki Hidayatullah Fadlullah, Ritu Chaudhary, Jameel Muzaffar, Kedar Kirtane, Yuan Liu, Georgia Z. Chen, Dong M. Shin, Yong Teng, Christine H. Chung
Summary: PD-1 therapy is standard treatment for recurrent metastatic head and neck squamous cell carcinoma. The combination of Pembrolizumab and Cabozantinib shows promising clinical activity. Further research is needed.
Article
Oncology
Helene Carinato, Mickael Burgy, Regine Ferry, Cathie Fischbach, Michal Kalish, Sebastien Guihard, Youssef Brahimi, Henri Flesch, Guy Bronner, Philippe Schultz, Veronique Frasie, Alicia Thiery, Martin Demarchi, Thierry Petit, Alain C. Jung, Pierre Wagner, Pierre Coliat, Christian Borel
Summary: The weekly PCC regimen appears to be a viable option for cisplatin-unfit patients, showing favorable PFS and OS compared to the EXTREME regimen. The study also demonstrates a high disease control rate and manageable toxicities in a more fragile patient population.
FRONTIERS IN ONCOLOGY
(2021)
Article
Multidisciplinary Sciences
Takahiro Wakasaki, Tomomi Manako, Ryuji Yasumatsu, Hirotaka Hara, Satoshi Toh, Muneyuki Masuda, Moriyasu Yamauchi, Yuichiro Kuratomi, Emi Nishimura, Toranoshin Takeuchi, Mioko Matsuo, Rina Jiromaru, Kazuki Hashimoto, Noritaka Komune, Takashi Nakagawa
Summary: The study showed that patients receiving Cmab had significantly better overall survival and progression-free survival compared to those using PTX. However, the incidence of drug-induced interstitial pneumonia in patients receiving SCT treatment was 21.2%.
Article
Dentistry, Oral Surgery & Medicine
Luciana Yamamoto de Almeida, Fernanda Dos Santos Moreira, Guilherme Augusto Silva Dos Santos, Florence Juana Maria Cuadra Zelaya, Cesar Alexander Ortiz, Michelle Agostini, Flavia Sammartino Mariano, Debora Campanella Bastos, Ulisses Ribaldo Nicolau Daher, Luiz Paulo Kowalski, Ricardo D. Coletta, Edgard Graner
Summary: The study found that orlistat can increase the sensitivity of SCC-9 LN-1 cells to cisplatin and paclitaxel chemotherapy drugs by downregulating the levels of Cyclin B1. However, the inhibitory effects on proliferation, migration, and invasion of SCC-9 LN-1 cells induced by orlistat in combination with cisplatin or paclitaxel were not significantly superior to using chemotherapy drugs alone.
Article
Oncology
Jordi Rubio-Casadevall, Beatriz Cirauqui Cirauqui, Javier Martinez Trufero, Maria Plana Serrahima, Almudena Garcia Castano, Alberto Carral Maseda, Lara Iglesias Docampo, Pedro Perez Segura, Isaac Ceballos Lenza, Vanesa Gutierrez Calderon, Jose Fuster Salva, Carolina Pena Alvarez, Irene Hernandez, Edel del Barco Morillo, Manuel Chaves Conde, Joaquina Martinez Galan, Marisa Duran Sanchez, Vanesa Quiroga, Eugenia Ortega, Ricard Mesia
Summary: This study confirms the real-world efficacy and tolerability of ERBITAX as first-line treatment in recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) when cisplatin-based chemotherapy is not feasible. Patients treated with immunotherapy after ERBITAX showed better overall survival.
FRONTIERS IN ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Zijing Liu, Zhuangzhuang Zheng, Lihua Dong, Xiao Guo, Xiaojing Jia, Jianfeng Wang, Lingbin Meng, Xiangyan Cui, Xin Jiang
Summary: Apatinib showed good efficacy and mild adverse effects in the treatment of patients with recurrence or metastasis inoperable head and neck squamous cell carcinoma. It can be considered as a second-line or above-line treatment option for these patients.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Neus Baste, Prakash Neupane, Ase Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, Danny Rischin
Summary: The study presents a post hoc analysis of the long-term efficacy and progression-free survival in recurrent/metastatic head and neck squamous cell carcinoma patients treated with pembrolizumab and pembrolizumab-chemotherapy as next-line therapy. The results demonstrate favorable clinical efficacy and progression-free survival with pembrolizumab and pembrolizumab-chemotherapy in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) >= 20, CPS >= 1, and total populations. Subsequent treatments after pembrolizumab-based therapy also showed good efficacy.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Felix Keil, Maximilian Hartl, Gabriela Altorjai, Andrea Berghold, Regina Riedl, Martin Pecherstorfer, Beate Mayrbaeurl, Alexander De Vries, Judith Schuster, Jutta Hackl, Thorsten Fuereder, Thomas Melchardt, Martin Burian, Richard Greil
Summary: This study compared the efficacy of TPF with TP + cetuximab in SCCHN patients, showing a slightly higher overall response rate in the TPC arm than the TPF arm, but similar overall survival rates after 400 days of treatment initiation. TPC resulted in fewer adverse events, but greater skin toxicities. Most patients did not experience delays from the end of ICT to RT + C.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Alan L. Ho
Summary: This article discusses the application of immune checkpoint inhibitors in the treatment of head and neck squamous cell carcinoma, specifically the use of pembrolizumab in first-line therapy. Through a case study, the practical application of the KEYNOTE-048 study results in clinical practice is highlighted.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Hideki Tanaka, Tomohiro Enokida, Susumu Okano, Takao Fujisawa, Nobukazu Tanaka, Naohiro Takeshita, Ryutaro Onaga, Yuta Hoshi, Akihisa Wada, Masanobu Sato, Yuri Ueda, Makoto Tahara
Summary: PE-based chemotherapy following ICI treatment shows robust antitumor efficacy and induces tumor shrinkage even when ICI is not effective in R/M SCCHN patients.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Tien-Hua Chen, Yi-Ying Pan, Tsung-Lun Lee, Ling-Wei Wang, Shyh-Kuan Tai, Pen-Yuan Chu, Wen-Liang Lo, Cheng-Hsien Wu, Muh-Hwa Yang, Peter Mu-Hsin Chang
Summary: This study investigated the treatment outcomes and clinical factors associated with better survival outcomes in patients with locally recurrent and distant metastatic squamous cell carcinoma of the head and neck who were treated with a cetuximab-containing regimen. The results showed that patients with local recurrence had longer overall survival and progression-free survival compared to those with distant metastasis, and there were more patients with oral cavity cancer and early recurrence within 6 months after radiation therapy in the local recurrence group.